<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37623461</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1210</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm13081210</ELocationID><Abstract><AbstractText>Hypophysitis, a rare inflammatory disorder of the pituitary gland, has seen an uptick in reported cases in recent years. Our objective is to summarize the most recent research on the etiopathogenesis, molecular mechanisms, and genetics of both primary and secondary hypophysitis. Primary autoimmune hypophysitis (PAH): During the acute phase of the disease, the pituitary gland in enlarged due to the infiltration of T and B lymphocytes. The chronic phase is characterized by progressive and irreversible pituitary atrophy. APA may play a role in the management, diagnosis, and prognosis of PAH. Specific autoantibodies such as anti-GH, anti-PIT-1, and anti-T-PIT have been found in patients with hypophysitis and hypopituitarism. A recent study suggested that a mechanism of escaping clonal deletion and mounting an immune response against self antigens can explain the unusual nature of the immune response observed in PAH patients. A cytokine array shows the presence of gamma-interferon and interleukin-17. Patients carrying mutations in the PIT1 or PROP1 genes may present PAH. Individuals carrying the HLA DQ8 haplotype are four times more likely to develop PAH. Immune checkpoint inhibitors induce hypophysitis (IIHs): IIHs is an increasingly frequent toxicity of in patients on treatment with inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1). ICIs inhibit the CTLA-4 pathway, leading to overactivation of T lymphocytes. The binding of PD-1/PD-L1 suppresses the activity of T cells, promotes the conversion of T-helpers into T-regulatory cells, and activates pro-survival signaling pathways in cancer cells. Cytokines play a crucial role in IIHs. B-cell infiltration has been observed in IIHs, suggesting that antibody-mediated pituitary injury may contribute. Genetic polymorphisms of CTLA-4 and PD-1 genes can increase the risk of IIHs. HLA alleles may also be involved in the onset of IIHs; this HLA association presents a possible alternative mechanistic hypothesis. IIHs may also be linked to a paraneoplastic syndrome triggered by ectopic expression of pituitary specific antigens. SARS-CoV-2-related hypophysitis: Recently, the literature has reported occurrences of hypophysitis associated with the SARS-CoV-2 virus; long COVID-19 may also present as infundibulo-neuro-hypophysitis. The virus enters the central nervous system because of its distinct interaction with angiotensin-converting enzyme receptors via spike proteins binding the capillary endothelium, and it directly damages the pituitary cells. The effect of SARS-CoV-2 can occur indirectly through inflammation and the release of cytokines. The exact mechanism remains ambiguous. The available data on endocrine complications associated with the SARS-CoV-2 vaccine are scant. Nonetheless, isolated cases of hypophysitis have been documented. Treatment of hypophysitis: Glucocorticoids are the cornerstone in managing primary hypophysitis, given their targeted action on inflammation. A better understanding of the etiopathogenesis and molecular mechanism of hypophysitis can lead to more effective and personalized treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Menotti</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3256-3206</Identifier><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giampietro</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raia</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0004-1205-0352</Identifier><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veleno</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelini</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglione</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3896-4078</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiodiagnostic, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudino</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1681-4343</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiodiagnostic, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doglietto</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7438-0734</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marinis</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvi</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiloiro</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Metabolism, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune</Keyword><Keyword MajorTopicYN="N">hypophysitis</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>25</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>25</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37623461</ArticleId><ArticleId IdType="pmc">PMC10455260</ArticleId><ArticleId IdType="doi">10.3390/jpm13081210</ArticleId><ArticleId IdType="pii">jpm13081210</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiloiro S., Capoluongo E.D., Tartaglione T., Giampietro A., Bianchi A., Giustina A., Pontecorvi A., De Marinis L. The Changing Clinical Spectrum of Hypophysitis. Trends Endocrinol. Metab. 2019;30:590&#x2013;602. doi: 10.1016/j.tem.2019.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2019.06.004</ArticleId><ArticleId IdType="pubmed">31345630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacques J.P., Valadares L.P., Moura A.C., Oliveira M.R.F., Naves L.A. Frequency and Clinical Characteristics of Hypophysitis and Hypopituitarism in Patients Undergoing Immunotherapy&#x2014;A Systematic Review. Front. Endocrinol. 2023;14:1091185. doi: 10.3389/fendo.2023.1091185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1091185</ArticleId><ArticleId IdType="pmc">PMC9974646</ArticleId><ArticleId IdType="pubmed">36875457</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D.B., Nebhan C.A., Moslehi J.J., Balko J.M. Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity. Nat. Rev. Clin. Oncol. 2022;19:254&#x2013;267. doi: 10.1038/s41571-022-00600-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00600-w</ArticleId><ArticleId IdType="pmc">PMC8790946</ArticleId><ArticleId IdType="pubmed">35082367</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlois F., Varlamov E.V., Fleseriu M. Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. J. Clin. Endocrinol. Metab. 2022;107:10&#x2013;28. doi: 10.1210/clinem/dgab672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab672</ArticleId><ArticleId IdType="pmc">PMC8684465</ArticleId><ArticleId IdType="pubmed">34528683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawanduzy C.A., Winkler-Schwartz A., Couldwell W.T. Hypophysitis: Defining Histopathologic Variants and a Review of Emerging Clinical Causative Entities. Int. J. Mol. Sci. 2023;24:5917. doi: 10.3390/ijms24065917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065917</ArticleId><ArticleId IdType="pmc">PMC10057821</ArticleId><ArticleId IdType="pubmed">36982990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bando H., Kanie K., Takahashi Y. Paraneoplastic Autoimmune Hypophysitis: An Emerging Concept. Best. Pract. Res. Clin. Endocrinol. Metab. 2022;36:101601. doi: 10.1016/j.beem.2021.101601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2021.101601</ArticleId><ArticleId IdType="pubmed">34876362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., Iguchi G., Bando H., Kanie K., Hidaka-Takeno R., Fukuoka H., Takahashi Y. Autoimmune Pituitary Disease: New Concepts with Clinical Implications. Endocr. Rev. 2020;41:261&#x2013;272. doi: 10.1210/endrev/bnz003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnz003</ArticleId><ArticleId IdType="pubmed">31513261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanie K., Iguchi G., Bando H., Urai S., Shichi H., Fujita Y., Matsumoto R., Suda K., Yamamoto M., Fukuoka H., et al. Mechanistic Insights into Immune Checkpoint Inhibitor-Related Hypophysitis: A Form of Paraneoplastic Syndrome. Cancer Immunol. Immunother. 2021;70:3669&#x2013;3677. doi: 10.1007/s00262-021-02955-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-021-02955-y</ArticleId><ArticleId IdType="pmc">PMC8571153</ArticleId><ArticleId IdType="pubmed">33977343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ach T., Kammoun F., El Fekih H., Slama N.B.H., Kahloun S., Fredj F.B., Laouani C., Ach K. Central Diabetes Insipidus Revealing a Hypophysitis Induced by SARS-CoV-2 Vaccine. Therapies. 2022;78:453&#x2013;455. doi: 10.1016/j.therap.2022.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2022.09.007</ArticleId><ArticleId IdType="pmc">PMC9553229</ArticleId><ArticleId IdType="pubmed">36280400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ach T., El Euch M. The Need to Shed Light on Potential Insidious SARS-CoV-2 Post-Vaccination Pituitary Lesions. Therapies. 2022;78:456&#x2013;457. doi: 10.1016/j.therap.2022.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2022.11.012</ArticleId><ArticleId IdType="pmc">PMC9737505</ArticleId><ArticleId IdType="pubmed">36566161</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J., Scorza F.A. The Pituitary Gland in SARS-CoV-2 Infections, Vaccinations, and Post-COVID Syndrome. Clinics. 2023;78:100157. doi: 10.1016/j.clinsp.2022.100157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinsp.2022.100157</ArticleId><ArticleId IdType="pmc">PMC9771751</ArticleId><ArticleId IdType="pubmed">36681069</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi M., Gunawardena S., Goenka A., Ey E., Kumar G. Post COVID-19 Lymphocytic Hypophysitis: A Rare Presentation. Child. Neurol. Open. 2022;9 doi: 10.1177/2329048X221103051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2329048X221103051</ArticleId><ArticleId IdType="pmc">PMC9125064</ArticleId><ArticleId IdType="pubmed">35615060</ArticleId></ArticleIdList></Reference><Reference><Citation>Castinetti F., Albarel F., Archambeaud F., Bertherat J., Bouillet B., Buffier P., Briet C., Cariou B., Caron P., Chabre O., et al. French Endocrine Society Guidance on Endocrine Side Effects of Immunotherapy. Endocr. Relat. Cancer. 2019;26:G1&#x2013;G18. doi: 10.1530/ERC-18-0320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-18-0320</ArticleId><ArticleId IdType="pmc">PMC6347286</ArticleId><ArticleId IdType="pubmed">30400055</ArticleId></ArticleIdList></Reference><Reference><Citation>Husebye E.S., Castinetti F., Criseno S., Curigliano G., Decallonne B., Fleseriu M., Higham C.E., Lupi I., Paschou S.A., Toth M., et al. Endocrine-Related Adverse Conditions in Patients Receiving Immune Checkpoint Inhibition: An ESE Clinical Practice Guideline. Eur. J. Endocrinol. 2022;187:G1&#x2013;G21. doi: 10.1530/EJE-22-0689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-22-0689</ArticleId><ArticleId IdType="pmc">PMC9641795</ArticleId><ArticleId IdType="pubmed">36149449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Russo F., Tartaglione T., Capoluongo E.D. Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice. J. Pers. Med. 2021;11:1026. doi: 10.3390/jpm11101026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11101026</ArticleId><ArticleId IdType="pmc">PMC8537090</ArticleId><ArticleId IdType="pubmed">34683167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cironi K.A., Decater T., Iwanaga J., Dumont A.S., Tubbs R.S. Arterial Supply to the Pituitary Gland: A Comprehensive Review. World Neurosurg. 2020;142:206&#x2013;211. doi: 10.1016/j.wneu.2020.06.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2020.06.221</ArticleId><ArticleId IdType="pubmed">32634634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzou S.-C., Landek-Salgado M.A., Kimura H., Caturegli P. Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis. J. Vis. Exp. 2010:e2181. doi: 10.3791/2181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2181</ArticleId><ArticleId IdType="pmc">PMC3159652</ArticleId><ArticleId IdType="pubmed">21206466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi I., Zhang J., Gutenberg A., Landek-Salgado M., Tzou S.-C., Mori S., Caturegli P. From Pituitary Expansion to Empty Sella: Disease Progression in a Mouse Model of Autoimmune Hypophysitis. Endocrinology. 2011;152:4190&#x2013;4198. doi: 10.1210/en.2011-1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-1004</ArticleId><ArticleId IdType="pmc">PMC3198994</ArticleId><ArticleId IdType="pubmed">21862619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Giampietro A., Bianchi A., Tartaglione T., Capobianco A., Anile C., De Marinis L. DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: A Comprehensive Review. Eur. J. Endocrinol. 2017;177:R275&#x2013;R285. doi: 10.1530/EJE-17-0505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-17-0505</ArticleId><ArticleId IdType="pubmed">28780516</ArticleId></ArticleIdList></Reference><Reference><Citation>Naran J., Can A.S. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2023. Lymphocytic Hypophysitis.</Citation></Reference><Reference><Citation>O&#x2019;Dwyer D.T., Smith A.I., Matthew M.L., Andronicos N.M., Ranson M., Robinson P.J., Crock P.A. Identification of the 49-KDa Autoantigen Associated with Lymphocytic Hypophysitis as &#x3b1;-Enolase. J. Clin. Endocrinol. Metab. 2002;87:752&#x2013;757. doi: 10.1210/jcem.87.2.8205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.2.8205</ArticleId><ArticleId IdType="pubmed">11836316</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi M.N., Whitelaw B.C., Carroll P.V. MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: Diagnosis and Treatment. Eur. J. Endocrinol. 2018;179:R151&#x2013;R163. doi: 10.1530/EJE-17-0009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-17-0009</ArticleId><ArticleId IdType="pubmed">29880706</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;re U., De Bellis A., Harput M.V., Bellastella G., Topcuoglu M., Yaltirik C.K., Cirillo P., Yola R.N., Sav A., Kelestimur F. Hypothalamitis: A Novel Autoimmune Endocrine Disease. A Literature Review and Case Report. J. Clin. Endocrinol. Metab. 2021;106:e415&#x2013;e429. doi: 10.1210/clinem/dgaa771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa771</ArticleId><ArticleId IdType="pubmed">33104773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalan P., Thomas N., Caturegli P. Th17 Cells Contribute to the Pathology of Autoimmune Hypophysitis. J. Immunol. 2021;206:2536&#x2013;2543. doi: 10.4049/jimmunol.2001073.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2001073</ArticleId><ArticleId IdType="pmc">PMC9245460</ArticleId><ArticleId IdType="pubmed">34011522</ArticleId></ArticleIdList></Reference><Reference><Citation>Falorni A., Minarelli V., Bartoloni E., Alunno A., Gerli R. Diagnosis and Classification of Autoimmune Hypophysitis. Autoimmun. Rev. 2014;13:412&#x2013;416. doi: 10.1016/j.autrev.2014.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.01.021</ArticleId><ArticleId IdType="pubmed">24434361</ArticleId></ArticleIdList></Reference><Reference><Citation>Force B.K., Vogel T.P., Nguyen D.M., Heck K.A., Sebastian S., Takashima M., Yoshor D., Samson S.L. A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient with a Background of Crohn&#x2019;s Disease&#x2014;A Case Report. Front. Endocrinol. 2020;11:350. doi: 10.3389/fendo.2020.00350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00350</ArticleId><ArticleId IdType="pmc">PMC7272571</ArticleId><ArticleId IdType="pubmed">32547497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbi S., Hannah-Shmouni F., Verbalis J.G., Koch C.A. Hypophysitis: An Update on the Novel Forms, Diagnosis and Management of Disorders of Pituitary Inflammation. Best. Pract. Res. Clin. Endocrinol. Metab. 2019;33:101371. doi: 10.1016/j.beem.2019.101371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2019.101371</ArticleId><ArticleId IdType="pmc">PMC7078033</ArticleId><ArticleId IdType="pubmed">31866206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunn B.H.M., Martin W.G., Simpson S., Mclean C.A. Idiopathic Granulomatous Hypophysitis: A Systematic Review of 82 Cases in the Literature. Pituitary. 2014;17:357&#x2013;365. doi: 10.1007/s11102-013-0510-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-013-0510-4</ArticleId><ArticleId IdType="pmc">PMC4085501</ArticleId><ArticleId IdType="pubmed">23990347</ArticleId></ArticleIdList></Reference><Reference><Citation>Radojkovic D., Pesic M., Dimic D., Radjenovic Petkovic T., Radenkovic S., Velojic-Golubovic M., Novak V., Ilic I., Radojkovic M. Localised Langerhans Cell Histiocytosis of the Hypothalamic-Pituitary Region: Case Report and Literature Review. Hormones. 2018;17:119&#x2013;125. doi: 10.1007/s42000-018-0024-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42000-018-0024-6</ArticleId><ArticleId IdType="pubmed">29858859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wu H., Bao X., Wang R. Lymphocytic Hypophysitis Secondary to Ruptured Rathke Cleft Cyst: Case Report and Literature Review. World Neurosurg. 2018;114:172&#x2013;177. doi: 10.1016/j.wneu.2018.03.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2018.03.086</ArticleId><ArticleId IdType="pubmed">29572168</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCou S., Recinos P.F., Prayson R.A., Karakasis C., Haider A., Patel N. Successful Immunomodulatory Treatment for Recurrent Xanthogranulomatous Hypophysitis in an Adolescent: Illustrative Case. J. Neurosurg. Case Lessons. 2022;4:CASE22191. doi: 10.3171/CASE22191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/CASE22191</ArticleId><ArticleId IdType="pmc">PMC9426350</ArticleId><ArticleId IdType="pubmed">36051774</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikuma J., Kan K., Ito R., Hara K., Sakai H., Miwa T., Kanazawa A., Odawara M. Critical Review of IgG4-Related Hypophysitis. Pituitary. 2017;20:282&#x2013;291. doi: 10.1007/s11102-016-0773-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-016-0773-7</ArticleId><ArticleId IdType="pubmed">27812776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen K.C.J., Popovic V., Trainer P.J. New Causes of Hypophysitis. Best. Pract. Res. Clin. Endocrinol. Metab. 2019;33:101276. doi: 10.1016/j.beem.2019.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2019.04.010</ArticleId><ArticleId IdType="pubmed">31078416</ArticleId></ArticleIdList></Reference><Reference><Citation>Landek-Salgado M.A., Leporati P., Lupi I., Geis A., Caturegli P. Growth Hormone and Proopiomelanocortin Are Targeted by Autoantibodies in a Patient with Biopsy-Proven IgG4-Related Hypophysitis. Pituitary. 2012;15:412&#x2013;419. doi: 10.1007/s11102-011-0338-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-011-0338-8</ArticleId><ArticleId IdType="pubmed">21861119</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bellis A., Bizzarro A., Bellastella A. Pituitary Antibodies and Lymphocytic Hypophysitis. Best. Pract. Res. Clin. Endocrinol. Metab. 2005;19:67&#x2013;84. doi: 10.1016/j.beem.2004.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2004.11.007</ArticleId><ArticleId IdType="pubmed">15826923</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bellis A., Bizzarro A., Perrino S., Coronella C., Conte M., Pasquali D., Sinisi A.A., Betterle C., Bellastella A. Characterization of Antipituitary Antibodies Targeting Pituitary Hormone-Secreting Cells in Idiopathic Growth Hormone Deficiency and Autoimmune Endocrine Diseases. Clin. Endocrinol. 2005;63:45&#x2013;49. doi: 10.1111/j.1365-2265.2005.02296.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2005.02296.x</ArticleId><ArticleId IdType="pubmed">15963060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi I., Manetti L., Raffaelli V., Grasso L., Sardella C., Cosottini M., Iannelli A., Gasperi M., Bogazzi F., Caturegli P., et al. Pituitary Autoimmunity Is Associated with Hypopituitarism in Patients with Primary Empty Sella. J. Endocrinol. Investig. 2011;34:e240-4. doi: 10.3275/7758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3275/7758</ArticleId><ArticleId IdType="pubmed">21623153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Tartaglione T., Angelini F., Bianchi A., Arena V., Giampietro A., Mormando M., Sciandra M., Laino M.E., De Marinis L. An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Prospective Single-Center Experience. Neuroendocrinology. 2017;104:280&#x2013;290. doi: 10.1159/000446544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446544</ArticleId><ArticleId IdType="pubmed">27165294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mele C., Pingue V., Caputo M., Zavattaro M., Pagano L., Prodam F., Nardone A., Aimaretti G., Marzullo P. Neuroinflammation and Hypothalamo-Pituitary Dysfunction: Focus of Traumatic Brain Injury. Int. J. Mol. Sci. 2021;22:2686. doi: 10.3390/ijms22052686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052686</ArticleId><ArticleId IdType="pmc">PMC7961958</ArticleId><ArticleId IdType="pubmed">33799967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Giampietro A., Angelini F., Arena V., Stigliano E., Tartaglione T., Mattogno P.P., D&#x2019;Alessandris Q.G., Lauretti L., Pontecorvi A., et al. Markers of Humoral and Cell-Mediated Immune Response in Primary Autoimmune Hypophysitis: A Pilot Study. Endocrine. 2021;73:308&#x2013;315. doi: 10.1007/s12020-021-02612-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02612-5</ArticleId><ArticleId IdType="pmc">PMC8263439</ArticleId><ArticleId IdType="pubmed">33484410</ArticleId></ArticleIdList></Reference><Reference><Citation>Crock P.A. Cytosolic Autoantigens in Lymphocytic Hypophysitis. J. Clin. Endocrinol. Metab. 1998;83:609&#x2013;618. doi: 10.1210/jc.83.2.609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.83.2.609</ArticleId><ArticleId IdType="pubmed">9467582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Tartaglione T., Capoluongo E.D., Angelini F., Arena V., Giampietro A., Bianchi A., Zoli A., Pontecorvi A., Colosimo C., et al. Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. J. Clin. Endocrinol. Metab. 2018;103:3877&#x2013;3889. doi: 10.1210/jc.2018-01021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2018-01021</ArticleId><ArticleId IdType="pubmed">30085134</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C.J.A., Bensing S., Burns C., Robinson P.J., Kasperlik-Zaluska A.A., Scott R.J., K&#xe4;mpe O., Crock P.A. Identification of TPIT and Other Novel Autoantigens in Lymphocytic Hypophysitis; Immunoscreening of a Pituitary CDNA Library and Development of Immunoprecipitation Assays. Eur. J. Endocrinol. 2012;166:391&#x2013;398. doi: 10.1530/EJE-11-1015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-11-1015</ArticleId><ArticleId IdType="pmc">PMC3290121</ArticleId><ArticleId IdType="pubmed">22193973</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwama S., Sugimura Y., Kiyota A., Kato T., Enomoto A., Suzuki H., Iwata N., Takeuchi S., Nakashima K., Takagi H., et al. Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-Neurohypophysitis. J. Clin. Endocrinol. Metab. 2015;100:E946&#x2013;E954. doi: 10.1210/jc.2014-4209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-4209</ArticleId><ArticleId IdType="pmc">PMC5393526</ArticleId><ArticleId IdType="pubmed">25919460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota A., Iwama S., Sugimura Y., Takeuchi S., Takagi H., Iwata N., Nakashima K., Suzuki H., Nishioka T., Kato T., et al. Identification of the Novel Autoantigen Candidate Rab GDP Dissociation Inhibitor Alpha in Isolated Adrenocorticotropin Deficiency. Endocr. J. 2015;62:153&#x2013;160. doi: 10.1507/endocrj.EJ14-0369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ14-0369</ArticleId><ArticleId IdType="pubmed">25346144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kume Y., Sakuma H., Sekine H., Sumikoshi M., Sugimura Y., Hosoya M. Lymphocytic Infundibuloneurohypophysitis with Positive Anti-Rabphilin-3A Antibodies Nine Years Post-Onset of Central Diabetes Insipidus. Clin. Pediatr. Endocrinol. 2021;30:65&#x2013;69. doi: 10.1297/cpe.30.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1297/cpe.30.65</ArticleId><ArticleId IdType="pmc">PMC7783119</ArticleId><ArticleId IdType="pubmed">33446956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen C., Hansen D., Husby S., Jacobsen B.B., Lillevang S.T. Association of a Putative Regulatory Polymorphism in the PD-1 Gene with Susceptibility to Type 1 Diabetes. Tissue Antigens. 2003;62:492&#x2013;497. doi: 10.1046/j.1399-0039.2003.00136.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1399-0039.2003.00136.x</ArticleId><ArticleId IdType="pubmed">14617032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H.-H., Gutenberg A., Chen T.-Y., Tsai N.-M., Lee C.-J., Cheng Y.-C., Cheng W.-H., Tzou Y.-M., Caturegli P., Tzou S.-C. In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis. Sci. Rep. 2017;7:43492. doi: 10.1038/srep43492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43492</ArticleId><ArticleId IdType="pmc">PMC5337949</ArticleId><ArticleId IdType="pubmed">28262761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Capoluongo E.D., Angelini F., Mariotti F., Grande G., Stigliano E., Vincenzoni F., Bianchi A., Giampietro A., Milardi D., et al. Autoantibody Reactivity Profile of Primary Autoimmune Hypophysitis Patients: Preliminary Results. Endocrine. 2022;76:224&#x2013;227. doi: 10.1007/s12020-021-02937-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02937-1</ArticleId><ArticleId IdType="pubmed">34797510</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffin-Sanson M.-L., Massias J.F., Ankotche A., Coste J., De Keyzer Y., Oliver C., Dumont C., Cabrol D., Ferr&#xe9; F., Bertagna X. High Precursor Level in Maternal Blood Results from the Alternate Mode of Proopiomelanocortin Processing in Human Placenta. Clin. Endocrinol. 1999;50:85&#x2013;94. doi: 10.1046/j.1365-2265.1999.00612.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2265.1999.00612.x</ArticleId><ArticleId IdType="pubmed">10341860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Giampietro A., Bianchi A., Menotti S., Angelini F., Tartaglione T., Antonini Cappellini G.C., De Galitiis F., Rossi E., Schinzari G., et al. Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? J. Pers. Med. 2023;13:415. doi: 10.3390/jpm13030415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm13030415</ArticleId><ArticleId IdType="pmc">PMC10056499</ArticleId><ArticleId IdType="pubmed">36983597</ArticleId></ArticleIdList></Reference><Reference><Citation>Penta L., Bizzarri C., Panichi M., Novelli A., Lepri F.R., Cappa M., Esposito S. Identification of a Novel PROP1 Mutation in a Patient with Combined Pituitary Hormone Deficiency and Enlarged Pituitary. Int. J. Mol. Sci. 2019;20:1875. doi: 10.3390/ijms20081875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20081875</ArticleId><ArticleId IdType="pmc">PMC6515070</ArticleId><ArticleId IdType="pubmed">30988269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertko E., Klammt J., Dusatkova P., Bahceci M., Gonc N., ten Have L., Kandemir N., Mansmann G., Obermannova B., Oostdijk W., et al. Combined Pituitary Hormone Deficiency Due to Gross Deletions in the POU1F1 (PIT-1) and PROP1 Genes. J. Hum. Genet. 2017;62:755&#x2013;762. doi: 10.1038/jhg.2017.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2017.34</ArticleId><ArticleId IdType="pmc">PMC5537413</ArticleId><ArticleId IdType="pubmed">28356564</ArticleId></ArticleIdList></Reference><Reference><Citation>Beressi N., Beressi J.P., Cohen R., Modigliani E. Lymphocytic Hypophysitis. A Review of 145 Cases. Ann. Med. Interne. 1999;150:327&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">10519020</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney A.P., Sumerel B., Rajalingam R., Bergsneider M., Yong W.H., Liau L.M. HLA Markers DQ8 and DR53 Are Associated with Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. J. Clin. Endocrinol. Metab. 2015;100:4092&#x2013;4097. doi: 10.1210/jc.2015-2702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2015-2702</ArticleId><ArticleId IdType="pubmed">26317559</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S., Capoluongo E.D., Tartaglione T., Bianchi A., Giampietro A., Angelini F., Arena V., Pontecorvi A., De Marinis L. Human Leucocyte Antigens Coeliac Haplotypes and Primary Autoimmune Hypophysitis in Caucasian Patients. Clin. Endocrinol. 2018;88:692&#x2013;699. doi: 10.1111/cen.13566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.13566</ArticleId><ArticleId IdType="pubmed">29418012</ArticleId></ArticleIdList></Reference><Reference><Citation>Megiorni F., Mora B., Bonamico M., Barbato M., Nenna R., Maiella G., Lulli P., Mazzilli M.C. HLA-DQ and Risk Gradient for Celiac Disease. Hum. Immunol. 2009;70:55&#x2013;59. doi: 10.1016/j.humimm.2008.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.10.018</ArticleId><ArticleId IdType="pubmed">19027045</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J.-C.D., Zhang X., Fedorov A.A., Nathenson S.G., Almo S.C. Structural Basis for Co-Stimulation by the Human CTLA-4/B7-2 Complex. Nature. 2001;410:604&#x2013;608. doi: 10.1038/35069112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35069112</ArticleId><ArticleId IdType="pubmed">11279501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellastella G., Carbone C., Scappaticcio L., Cirillo P., Troiani T., Morgillo F., Vietri M.T., Della Corte C.M., De Falco V., Napolitano S., et al. Hypothalamic&#x2013;Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers. 2021;13:4036. doi: 10.3390/cancers13164036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13164036</ArticleId><ArticleId IdType="pmc">PMC8391584</ArticleId><ArticleId IdType="pubmed">34439190</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 Immunoreceptor Inhibits B Cell Receptor-Mediated Signaling by Recruiting Src Homology 2-Domain-Containing Tyrosine Phosphatase 2 to Phosphotyrosine. Proc. Natl. Acad. Sci. USA. 2001;98:13866&#x2013;13871. doi: 10.1073/pnas.231486598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.231486598</ArticleId><ArticleId IdType="pmc">PMC61133</ArticleId><ArticleId IdType="pubmed">11698646</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamper C.C., Zhang Y., Tobin J.F., Erbe D.V., Ikemizu S., Davis S.J., Stahl M.L., Seehra J., Somers W.S., Mosyak L. Crystal Structure of the B7-1/CTLA-4 Complex That Inhibits Human Immune Responses. Nature. 2001;410:608&#x2013;611. doi: 10.1038/35069118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35069118</ArticleId><ArticleId IdType="pubmed">11279502</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson B., Morganstein D.L. Endocrine Toxicity of Cancer Immunotherapy: Clinical Challenges. Endocr. Connect. 2021;10:R116&#x2013;R124. doi: 10.1530/EC-20-0489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EC-20-0489</ArticleId><ArticleId IdType="pmc">PMC8052567</ArticleId><ArticleId IdType="pubmed">33544091</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J. Exp. Med. 2000;192:1027&#x2013;1034. doi: 10.1084/jem.192.7.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.192.7.1027</ArticleId><ArticleId IdType="pmc">PMC2193311</ArticleId><ArticleId IdType="pubmed">11015443</ArticleId></ArticleIdList></Reference><Reference><Citation>Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., et al. PD-L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation. Nat. Immunol. 2001;2:261&#x2013;268. doi: 10.1038/85330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85330</ArticleId><ArticleId IdType="pubmed">11224527</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat. Med. 2002;8:793&#x2013;800. doi: 10.1038/nm730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm730</ArticleId><ArticleId IdType="pubmed">12091876</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarnath S., Mangus C.W., Wang J.C.M., Wei F., He A., Kapoor V., Foley J.E., Massey P.R., Felizardo T.C., Riley J.L., et al. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Sci. Transl. Med. 2011;3:111ra120. doi: 10.1126/scitranslmed.3003130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003130</ArticleId><ArticleId IdType="pmc">PMC3235958</ArticleId><ArticleId IdType="pubmed">22133721</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma T., Yao S., Zhu G., Flies A.S., Flies S.J., Chen L. B7-H1 Is a Ubiquitous Antiapoptotic Receptor on Cancer Cells. Blood. 2008;111:3635&#x2013;3643. doi: 10.1182/blood-2007-11-123141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-11-123141</ArticleId><ArticleId IdType="pmc">PMC2275025</ArticleId><ArticleId IdType="pubmed">18223165</ArticleId></ArticleIdList></Reference><Reference><Citation>Queirolo P., Dozin B., Morabito A., Banelli B., Carosio R., Fontana V., Ferrucci P.F., Martinoli C., Cocorocchio E., Ascierto P.A., et al. CTLA-4 Gene Variant -1661A&amp;gt;G May Predict the Onset of Endocrine Adverse Events in Metastatic Melanoma Patients Treated with Ipilimumab. Eur. J. Cancer. 2018;97:59&#x2013;61. doi: 10.1016/j.ejca.2018.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2018.04.005</ArticleId><ArticleId IdType="pubmed">29743138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizukoshi T., Fukuoka H., Takahashi Y. Immune Checkpoint Inhibitor-Related Hypophysitis. Best. Pract. Res. Clin. Endocrinol. Metab. 2022;36:101668. doi: 10.1016/j.beem.2022.101668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2022.101668</ArticleId><ArticleId IdType="pubmed">35562229</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lffer M., Battke F., Schulze M., Feldhahn M., Flatz L., Martus P., Forschner A. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma. Cancers. 2022;14:302. doi: 10.3390/cancers14020302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14020302</ArticleId><ArticleId IdType="pmc">PMC8773840</ArticleId><ArticleId IdType="pubmed">35053465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Iwama S., Sugiyama D., Yasuda Y., Okuji T., Ito M., Ito S., Sugiyama M., Onoue T., Takagi H., et al. Anti-Pituitary Antibodies and Susceptible Human Leukocyte Antigen Alleles as Predictive Biomarkers for Pituitary Dysfunction Induced by Immune Checkpoint Inhibitors. J. Immunother. Cancer. 2021;9:e002493. doi: 10.1136/jitc-2021-002493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002493</ArticleId><ArticleId IdType="pmc">PMC8137231</ArticleId><ArticleId IdType="pubmed">34011534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kula A., Dawidowicz M., Kiczmer P., Prawdzic Se&#x144;kowska A., &#x15a;wi&#x119;tochowska E. The Role of Genetic Polymorphism within PD-L1 Gene in Cancer. Review. Exp. Mol. Pathol. 2020;116:104494. doi: 10.1016/j.yexmp.2020.104494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2020.104494</ArticleId><ArticleId IdType="pubmed">32679050</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulichino A.-M., Vallette-Kasic S., Couture C., Gauthier Y., Brue T., David M., Malpuech G., Deal C., Van Vliet G., De Vroede M., et al. Human and Mouse TPIT Gene Mutations Cause Early Onset Pituitary ACTH Deficiency. Genes Dev. 2003;17:711&#x2013;716. doi: 10.1101/gad.1065603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1065603</ArticleId><ArticleId IdType="pmc">PMC196015</ArticleId><ArticleId IdType="pubmed">12651888</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt Z., Kim S., Villanueva-Meyer J., Coupe C., Young A., Kang J.H., Yazdany J., Schmajuk G., Rush S., Ziv E., et al. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor&#x2013;Induced Hypophysitis. J. Endocr. Soc. 2023;7:bvad012. doi: 10.1210/jendso/bvad012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvad012</ArticleId><ArticleId IdType="pmc">PMC9969737</ArticleId><ArticleId IdType="pubmed">36860908</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y. The Novel Concept of &#x201c;Onco-Immuno-Endocrinology&#x201d; Led to the Discovery of New Clinical Entity &#x201c;Paraneoplastic Autoimmune Hypophysitis&#x201d;. Best. Pract. Res. Clin. Endocrinol. Metab. 2022;36:101663. doi: 10.1016/j.beem.2022.101663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2022.101663</ArticleId><ArticleId IdType="pubmed">35525821</ArticleId></ArticleIdList></Reference><Reference><Citation>Frara S., Allora A., Castellino L., di Filippo L., Loli P., Giustina A. COVID-19 and the Pituitary. Pituitary. 2021;24:465&#x2013;481. doi: 10.1007/s11102-021-01148-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-021-01148-1</ArticleId><ArticleId IdType="pmc">PMC8089131</ArticleId><ArticleId IdType="pubmed">33939057</ArticleId></ArticleIdList></Reference><Reference><Citation>Capatina C., Poiana C., Fleseriu M. Pituitary and SARS-CoV-2: An Unremitting Conundrum. Best. Pract. Res. Clin. Endocrinol. Metab. 2023:101752. doi: 10.1016/j.beem.2023.101752. in press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101752</ArticleId><ArticleId IdType="pmc">PMC9969757</ArticleId><ArticleId IdType="pubmed">36878774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L., Sun S., Zhang J., Zhu H., Xu Y., Ma Q., McNutt M.A., Korteweg C., Gu J. Endocrine Cells of the Adenohypophysis in Severe Acute Respiratory Syndrome (SARS)This Paper Is One of a Selection of Papers Published in This Special Issue Entitled &#x201c;Second International Symposium on Recent Advances in Basic, Clinical, and Social Medicine&#x201d; and Has Undergone the Journal&#x2019;s Usual Peer Review Process. Biochem. Cell Biol. 2010;88:723&#x2013;730. doi: 10.1139/O10-022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/O10-022</ArticleId><ArticleId IdType="pubmed">20651845</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow M.K.-S., Kwek D.S.-K., Ng A.W.-K., Ong K.-C., Kaw G.J.-L., Lee L.S.-U. Hypocortisolism in Survivors of Severe Acute Respiratory Syndrome (SARS) Clin. Endocrinol. 2005;63:197&#x2013;202. doi: 10.1111/j.1365-2265.2005.02325.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2005.02325.x</ArticleId><ArticleId IdType="pmc">PMC7188349</ArticleId><ArticleId IdType="pubmed">16060914</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host&#x2013;Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020;11:995&#x2013;998. doi: 10.1021/acschemneuro.0c00122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00122</ArticleId><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Gopalakrishnan M., Yadav P., Misra S. Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care. Indian. J. Endocrinol. Metab. 2020;24:381. doi: 10.4103/ijem.IJEM_440_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijem.IJEM_440_20</ArticleId><ArticleId IdType="pmc">PMC7810055</ArticleId><ArticleId IdType="pubmed">33489841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzek A., Gerling M., P&#xfc;schel K., Saeger W. Post-Mortem Histopathology of Pituitary and Adrenals of COVID-19 Patients. Leg. Med. 2022;57:102045. doi: 10.1016/j.legalmed.2022.102045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.legalmed.2022.102045</ArticleId><ArticleId IdType="pmc">PMC8873038</ArticleId><ArticleId IdType="pubmed">35334433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani M., Nakayama Y., Saitoh Y., Ariga H., Enokida T., Ishihara T., Sano T., Hirata Y., Katano H., Suzuki T., et al. Pathologic and Neuropathologic Study of a Case of COVID-19. JMA J. 2022;5:157&#x2013;160. doi: 10.31662/jmaj.2021-0178.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2021-0178</ArticleId><ArticleId IdType="pmc">PMC8827173</ArticleId><ArticleId IdType="pubmed">35224283</ArticleId></ArticleIdList></Reference><Reference><Citation>Misgar R.A., Rasool A., Wani A.I., Bashir M.I. Central Diabetes Insipidus (Infundibuloneuro Hypophysitis): A Late Complication of COVID-19 Infection. J. Endocrinol. Investig. 2021;44:2855&#x2013;2856. doi: 10.1007/s40618-021-01627-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-021-01627-z</ArticleId><ArticleId IdType="pmc">PMC8253675</ArticleId><ArticleId IdType="pubmed">34215999</ArticleId></ArticleIdList></Reference><Reference><Citation>Berni A., Malandrino D., Parenti G., Maggi M., Poggesi L., Peri A. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) Infection: May All Fit Together? J. Endocrinol. Investig. 2020;43:1137&#x2013;1139. doi: 10.1007/s40618-020-01301-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01301-w</ArticleId><ArticleId IdType="pmc">PMC7246958</ArticleId><ArticleId IdType="pubmed">32451971</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M., Cook A.R., Lim J.T., Sun Y., Dickens B.L. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J. Clin. Med. 2020;9:967. doi: 10.3390/jcm9040967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040967</ArticleId><ArticleId IdType="pmc">PMC7231098</ArticleId><ArticleId IdType="pubmed">32244365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachinidis A., Garyfallos A. COVID-19 Vaccination Can Occasionally Trigger Autoimmune Phenomena, Probably via Inducing Age-associated B Cells. Int. J. Rheum. Dis. 2022;25:83&#x2013;85. doi: 10.1111/1756-185X.14238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14238</ArticleId><ArticleId IdType="pmc">PMC8652459</ArticleId><ArticleId IdType="pubmed">34766739</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara L.J., Vera-Lastra O., Mahroum N., Pineda C., Shoenfeld Y. Autoimmune Post-COVID Vaccine Syndromes: Does the Spectrum of Autoimmune/Inflammatory Syndrome Expand? Clin. Rheumatol. 2022;41:1603&#x2013;1609. doi: 10.1007/s10067-022-06149-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06149-4</ArticleId><ArticleId IdType="pmc">PMC8979721</ArticleId><ArticleId IdType="pubmed">35378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Amereller F., K&#xfc;ppers A.-M., Schilbach K., Schopohl J., St&#xf6;rmann S. Clinical Characteristics of Primary Hypophysitis&#x2014;A Single-Centre Series of 60 Cases. Exp. Clin. Endocrinol. Diabetes. 2021;129:234&#x2013;240. doi: 10.1055/a-1163-7304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1163-7304</ArticleId><ArticleId IdType="pubmed">32770534</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa B., Shah R., Sarathi V., Lila A.R., Sehemby M.K., Patil V.A., Sankhe S., Shah N., Bandgar T. Early Pulse Glucocorticoid Therapy and Improved Hormonal Outcomes in Primary Hypophysitis. Neuroendocrinology. 2022;112:186&#x2013;195. doi: 10.1159/000516006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516006</ArticleId><ArticleId IdType="pubmed">33744880</ArticleId></ArticleIdList></Reference><Reference><Citation>Imga N.N., Yildirim A.E., Baser O.O., Berker D. Clinical and Hormonal Characteristics of Patients with Different Types of Hypophysitis: A Single-Center Experience. Arch. Endocrinol. Metab. 2019;63:47&#x2013;52. doi: 10.20945/2359-3997000000102.</Citation><ArticleIdList><ArticleId IdType="doi">10.20945/2359-3997000000102</ArticleId><ArticleId IdType="pmc">PMC10118843</ArticleId><ArticleId IdType="pubmed">30864631</ArticleId></ArticleIdList></Reference><Reference><Citation>Haanen J.B.A.G., Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2017;28:iv119&#x2013;iv142. doi: 10.1093/annonc/mdx225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx225</ArticleId><ArticleId IdType="pubmed">28881921</ArticleId></ArticleIdList></Reference><Reference><Citation>Faje A.T., Lawrence D., Flaherty K., Freedman C., Fadden R., Rubin K., Cohen J., Sullivan R.J. High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma. Cancer. 2018;124:3706&#x2013;3714. doi: 10.1002/cncr.31629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31629</ArticleId><ArticleId IdType="pubmed">29975414</ArticleId></ArticleIdList></Reference><Reference><Citation>Faje A. Hypophysitis: Evaluation and Management. Clin. Diabetes Endocrinol. 2016;2:15. doi: 10.1186/s40842-016-0034-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40842-016-0034-8</ArticleId><ArticleId IdType="pmc">PMC5471685</ArticleId><ArticleId IdType="pubmed">28702249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J.J., Wu C., Mehta N., Wald-Dickler N., Yang W., Qiao R. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients with COVID-19. J. Intensive Care Med. 2021;36:673&#x2013;680. doi: 10.1177/0885066621994057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066621994057</ArticleId><ArticleId IdType="pubmed">33632000</ArticleId></ArticleIdList></Reference><Reference><Citation>Taieb A., Mounira E.E. Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology. Vaccines. 2022;10:2004. doi: 10.3390/vaccines10122004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122004</ArticleId><ArticleId IdType="pmc">PMC9786744</ArticleId><ArticleId IdType="pubmed">36560413</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilli T., Dalmiglio C., Dalmazio G., Sagnella A., Forleo R., Brilli L., Maino F., Ciuoli C., Castagna M.G. No Need of Glucocorticoid Dose Adjustment in Patients with Adrenal Insufficiency before COVID-19 Vaccine. Eur. J. Endocrinol. 2022;187:K7&#x2013;K11. doi: 10.1530/EJE-21-1236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-21-1236</ArticleId><ArticleId IdType="pubmed">36073554</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers M.N., Topazian M.D., Khosroshahi A., Witzig T.E., Wallace Z.S., Hart P.A., Deshpande V., Smyrk T.C., Chari S., Stone J.H. Rituximab for IgG4-Related Disease: A Prospective, Open-Label Trial. Ann. Rheum. Dis. 2015;74:1171&#x2013;1177. doi: 10.1136/annrheumdis-2014-206605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206605</ArticleId><ArticleId IdType="pubmed">25667206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>